![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, August 23, 2013 3:08:05 PM
As the population ages, the market for Alzheimer's and cognitive disorders is exploding.
Current treatments stabilize symptoms only for a short period of time.
What is on the horizon for symptom improvement and disease modification from drug and device companies?
Session Chair: Christian Hordo, Senior Manager Business Development, Genentech
Genentech's mission is to develop drugs to address significant unmet medical
needs
Bjorn Larsson, Executive Chairman, Alzinova
Alzinova AB is a privately held Swedish biotechnology enterprise engaged in drug discovery research for Alzheimer’s disease
Hendrik Leibers, CFO, Probiodrug
Probiodrug AG is a biopharmaceutical company focused on the development of innovative oral drugs for the treatment of major age related diseases.
Koen de Witte, Managing Director, reMYND
reMYND drives the development of disease-modifying treatments against Alzheimer's, Parkinson's, Diabetes and other protein misfolding disorders
Gerald Commissiong, President & CEO, Amarantus Bioscience
Out of the 4 companies above, Amarantus is the best fit for a device company since it owns the Lympro Test, which is a device; a diagnostic product. Gerald could present the latest data from DBX and talk about the LymPro Test Kit. Doesn't sound right to talk about the old data
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM